retatrutide mechanism of action triple agonist glp-1 gip glucagon Glucagon-like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide, and Receptor Agonists in Metabolic Dysfunction-Associated Steatotic Liver Disease: Novel Medication in New Liver Disease Nomenclature From Obesity to Metabolic Health:
Description
A behavioral weight-lossintervention in persons with serious mental illness
Saxenda is a once-daily injection
Glucocorticoids suppress glp-1 secretion: possible contribution to their diabetogenic effects
The FDA has approved several GLP-1 agonist medicines for different uses
STEP-HFpEF Trial (NEJM, 2023): 13.3% weight loss plus major improvements in HFpEF symptoms and function
Patients should be advised to seek urgent medical attention (via NHS 111, A&E, or 999 if severely unwell) if they experience severe, persistent abdominal pain, particularly if radiating to the back, with or without vomiting
